Tag Archives: Patients

Injectafer (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia

BASKING RIDGE, N.J. and SHIRLEY, N.Y., May 6, 2021 /PRNewswire/ — Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult… Read More »

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

PARIS, March 31, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. “In the Phase 3 IKEMA study, the addition… Read More »

Texas hospitals dealt winter weather blow scramble to get clean water to patients

Some Texas hospital officials are scrambling to bring in clean water supply while delaying elective surgeries after brutal winter weather resulted in a gradually resolving power, and now emerging water, crisis this week. Texas authorities ordered 13 million people — nearly half of the population of the nation’s second-largest state — to boil tap water before drinking it because… Read More »

Anti-inflammatory drug improves survival in COVID-19 patients

Researchers from 68 sites across the country, led by David E. Leaf and Shruti Gupta  from the Division of Renal Medicine at Harvard-affiliated Brigham and Women’s Hospital, have investigated the effects of the anti-inflammatory drug tocilizumab on critically ill patients with laboratory-confirmed COVID-19. Unlike steroids, which suppress the immune system more broadly, tocilizumab specifically inhibits the receptor for… Read More »

Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients

As one of the hottest markets in pharmaceuticals, immunology has become a murderers’ row of blockbuster drugs in recent years. But Bristol Myers Squibb has big hopes for a next-gen entry in Zeposia, and it’s angling for a foothold in ulcerative colitis to get the ball rolling.  Zeposia helped 18.4% of ulcerative colitis patients reach clinical remission at… Read More »